TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Early Postoperative Decline
Brief Summary: The purpose of this trial is to determine whether using a brain training program in the time leading up to as well as after heart surgery will reduce confusion and cognitive loss that can occur after surgery.


Options:
A: Arm Label: CPAP therapy arm; Type: EXPERIMENTAL; Interventions: Other: CPAP treatment | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CPAP treatment; Assigned to Arm(s): CPAP therapy arm
B: Arm Label: Hydration: Normal Saline (salt water); Type: EXPERIMENTAL; Interventions: Drug: Saline | Arm Label: Placebo: Lower Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Hydration: Normal Saline (salt water) | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo: Lower Saline
C: Arm Label: Lumosity (CT Group); Type: EXPERIMENTAL; Interventions: Device: Lumosity | Arm Label: Usual Care (Control Group); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Lumosity; Assigned to Arm(s): Lumosity (CT Group)
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Multicomponent nurse-led intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multicomponent nurse-led intervention; Assigned to Arm(s): Intervention Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Early Postoperative Decline
Brief Summary: The purpose of this trial is to determine whether using a brain training program in the time leading up to as well as after heart surgery will reduce confusion and cognitive loss that can occur after surgery.


Options:
A: Arm Label: Lumosity (CT Group); Type: EXPERIMENTAL; Interventions: Device: Lumosity | Arm Label: Usual Care (Control Group); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Lumosity; Assigned to Arm(s): Lumosity (CT Group)
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Multicomponent nurse-led intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Multicomponent nurse-led intervention; Assigned to Arm(s): Intervention Group
C: Arm Label: Hydration: Normal Saline (salt water); Type: EXPERIMENTAL; Interventions: Drug: Saline | Arm Label: Placebo: Lower Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Hydration: Normal Saline (salt water) | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo: Lower Saline
D: Arm Label: Non-Clinically Assisted Hydration arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-Clinically Assisted Hydration arm | Arm Label: Clinically Assisted Hydration arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Clinically Assisted Hydration arm | Intervention Type: OTHER; Name: Non-Clinically Assisted Hydration arm; Assigned to Arm(s): Non-Clinically Assisted Hydration arm | Intervention Type: OTHER; Name: Clinically Assisted Hydration arm; Assigned to Arm(s): Clinically Assisted Hydration arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Weight reduction is the most important treatment target when polycystic ovary syndrome (PCOS) is linked to obesity. Liraglutide (LIRA) in dose of 3 mg was recently approved as an anti-obesity drug. Metformin could enhance weight lowering potential of liraglutide.

We investigates short term interventions with low dose liraglutide in combination with metformin and high dose liraglutide alone influence on significant weight reduction in obese women with PCOS.


Options:
A: Arm Label: liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: metformin and liraglutide; Type: EXPERIMENTAL; Interventions: Drug: metformin and liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: metformin and liraglutide; Assigned to Arm(s): metformin and liraglutide
B: Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): N/A
C: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32
D: Arm Label: Low Glycemic Index Diet Group; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index Diet Group | Arm Label: Conventional Diet Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Diet Group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Glycemic Index Diet Group; Assigned to Arm(s): Low Glycemic Index Diet Group | Intervention Type: OTHER; Name: Conventional Diet Group; Assigned to Arm(s): Conventional Diet Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM): A 12-month Study of the Impact of Combined Shared-decision Making and Brief Negotiated Interviewing on Disease Control and Medication Adherence in Patients With Diabetes
Brief Summary: The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with usual care. These engagement techniques include shared decision-making and brief negotiated interviewing and are delivered telephonically.


Options:
A: Arm Label: Training course for practice nurses in autonomy support; Type: EXPERIMENTAL; Interventions: Behavioral: Training course for practice nurses in autonomy support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training course for practice nurses in autonomy support; Assigned to Arm(s): Training course for practice nurses in autonomy support
B: Arm Label: MEDIC; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling and peer support, Behavioral: Interactive Education, Behavioral: Role modeling, Procedure: Pharmacologic case management | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling and peer support; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Interactive Education; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Role modeling; Assigned to Arm(s): MEDIC | Intervention Type: PROCEDURE; Name: Pharmacologic case management; Assigned to Arm(s): MEDIC
C: Arm Label: 1; Type: OTHER; Interventions: Behavioral: Cognitive Behavioral Intervention | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Office System Redesign Intervention | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Office System Redesign Intervention; Assigned to Arm(s): 2
D: Arm Label: Shared Decision Making/Brief Negotiated Interviewing; Type: OTHER; Interventions: Behavioral: Shared Decision Making | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making; Assigned to Arm(s): Shared Decision Making/Brief Negotiated Interviewing

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM): A 12-month Study of the Impact of Combined Shared-decision Making and Brief Negotiated Interviewing on Disease Control and Medication Adherence in Patients With Diabetes
Brief Summary: The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with usual care. These engagement techniques include shared decision-making and brief negotiated interviewing and are delivered telephonically.


Options:
A: Arm Label: Shared Decision Making/Brief Negotiated Interviewing; Type: OTHER; Interventions: Behavioral: Shared Decision Making | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making; Assigned to Arm(s): Shared Decision Making/Brief Negotiated Interviewing
B: Arm Label: Heart disease; Type: N/A; Interventions: N/A | Arm Label: Healthy adults; Type: N/A; Interventions: N/A
C: Arm Label: Decision aid plus YourDiseaseRisk; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based decision aid plus personalized risk assessment | Arm Label: Decision aid alone; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based decision aid alone | Arm Label: III; Type: SHAM_COMPARATOR; Interventions: Behavioral: Generic website | Intervention Type: BEHAVIORAL; Name: Web-based decision aid plus personalized risk assessment; Assigned to Arm(s): Decision aid plus YourDiseaseRisk | Intervention Type: BEHAVIORAL; Name: Web-based decision aid alone; Assigned to Arm(s): Decision aid alone | Intervention Type: BEHAVIORAL; Name: Generic website; Assigned to Arm(s): III
D: Arm Label: Control: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: DT LVAD Decision Support Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: DT LVAD Decision Support Intervention | Intervention Type: BEHAVIORAL; Name: DT LVAD Decision Support Intervention; Assigned to Arm(s): DT LVAD Decision Support Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Features and Prevalence of Asymptomatic Peripheral Artery Disease in Patients With Type 1 Diabetes Mellitus
Brief Summary: AIMS: Determining the clinical features and prevalence of peripheral artery disease (PAD) in asymptomatics patients with type 1 diabetes mellitus (T1DM) and checking the validity of the current recommendations regarding for PAD screening in T1DM.

METHODOLOGY: An observational and cross-sectional prevalence study. The whole group of patients (sample size calculated: 299 patients) will make the Edinburgh Questionnaire for detecting classic symptoms of intermittent claudication, and after verifying the absence of symptoms and exclusion criteria, they will be included in the study. All patients will undergo assessment of clinical parameters related to T1DM and classic cardiovascular risk factors, as well as, an analytical assessment of the lipid profile, HbA1c level, proinflammatory profile and oxidative stress status. They will also undergo a comprehensive anthropometric assessment including office blood pressure (BP) monitoring and ambulatory 24-hours BP monitoring in patients with an indication as routine clinical practice, assessment of cardioautonomic function, and lastly an ankle-brachial index (ABI) by Doppler ultrasound, in the context of routine clinical practice in patients with clinical indication, or as an extraordinary procedure for participating in the study in patients who do not meet criteria for screening according to current recommendations.


Options:
A: Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
B: Intervention Type: DIAGNOSTIC_TEST; Name: Transcutaneous pressure of oxygen (TcPO2); Assigned to Arm(s): N/A | Intervention Type: DIAGNOSTIC_TEST; Name: Toe Brachial Pressure Index (TBPI); Assigned to Arm(s): N/A | Intervention Type: DIAGNOSTIC_TEST; Name: Podiatry Ankle Duplex scan (PAD-scan); Assigned to Arm(s): N/A | Intervention Type: DIAGNOSTIC_TEST; Name: Duplex Assist; Assigned to Arm(s): N/A | Intervention Type: DIAGNOSTIC_TEST; Name: Ankle Brachial Pressure Index (ABPI); Assigned to Arm(s): N/A
C: N/A
D: Intervention Type: DIAGNOSTIC_TEST; Name: Stimulation TcPO2 test; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Introduction of a Uterine Balloon Tamponade for Postpartum Hemorrhage in Three Low Income Countries: a Stepped Wedge Cluster Randomized Trial
Brief Summary: This study is a prospective, systematic evaluation to assess the effectiveness and safety of introduction of UBT into PPH care at secondary level and district hospitals in 3 low-resource countries. The first component of the evaluation is a prospective stepped wedge cluster randomized design to assess the potential reduction in PPH-related mortality and invasive procedures (blood transfusion, arterial ligation, hysterectomy and uterine arterial embolization) for PPH performed at participating facilities following introduction of UBT. The second component is a nested cohort analysis to assess the safety and acceptability of UBT among women diagnosed with PPH.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: OTHER; Interventions: Device: non-pneumatic anti-shock garment | Intervention Type: DEVICE; Name: non-pneumatic anti-shock garment; Assigned to Arm(s): Intervention
B: Arm Label: Bakri balloon group; Type: ACTIVE_COMPARATOR; Interventions: Device: Bakri balloon | Arm Label: Condom loaded Foley's catheter group; Type: ACTIVE_COMPARATOR; Interventions: Device: Condom loaded foley's catheter | Intervention Type: DEVICE; Name: Bakri balloon; Assigned to Arm(s): Bakri balloon group | Intervention Type: DEVICE; Name: Condom loaded foley's catheter; Assigned to Arm(s): Condom loaded Foley's catheter group
C: Arm Label: Baseline period; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Uterine balloon tamponade; Type: EXPERIMENTAL; Interventions: Other: Uterine balloon tamponade | Intervention Type: OTHER; Name: Uterine balloon tamponade; Assigned to Arm(s): Uterine balloon tamponade
D: Arm Label: Early Belfort-Dildy balloon device; Type: EXPERIMENTAL; Interventions: Device: Early Belfort-Dildy Balloon | Arm Label: Late Belfort-Dildy balloon device; Type: OTHER; Interventions: Device: Late Belfort-Dildy balloon | Intervention Type: DEVICE; Name: Early Belfort-Dildy Balloon; Assigned to Arm(s): Early Belfort-Dildy balloon device | Intervention Type: DEVICE; Name: Late Belfort-Dildy balloon; Assigned to Arm(s): Late Belfort-Dildy balloon device

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese Polycystic Ovary Syndrome Women; A Quasi Experimental Study
Brief Summary: RCT to investigate whether metformin co-treatment would improve IVF outcomes in overweight and obese women with PCOS.


Options:
A: Arm Label: M: Metformin P: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Metformin / Placebo treatment for 4 months | Intervention Type: DRUG; Name: Metformin / Placebo treatment for 4 months; Assigned to Arm(s): M: Metformin P: Placebo
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Metformin-treated group; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin-treated group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo administration | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Experimental group | Intervention Type: DRUG; Name: Placebo administration; Assigned to Arm(s): Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Latinas LEarning About Density (LLEAD Study)
Brief Summary: This study will examine behavioral and psychological outcomes of breast density notification using a 3-group randomized design comparing usual written notification to two educationally enhanced approaches.


Options:
A: Arm Label: PREPARE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PREPARE Intervention; Assigned to Arm(s): PREPARE intervention
B: Arm Label: Behavioral Activation Treatment for Depression; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for Depression Treatment | Arm Label: Supportive Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Counseling | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for Depression Treatment; Assigned to Arm(s): Behavioral Activation Treatment for Depression | Intervention Type: BEHAVIORAL; Name: Supportive Counseling; Assigned to Arm(s): Supportive Counseling
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Enhanced; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written educational brochure | Arm Label: Interpersonal; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written educational brochure, Behavioral: Promotora interaction | Intervention Type: BEHAVIORAL; Name: Written educational brochure; Assigned to Arm(s): Enhanced, Interpersonal | Intervention Type: BEHAVIORAL; Name: Promotora interaction; Assigned to Arm(s): Interpersonal
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health Literacy-Focused High Blood Pressure Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Literacy-Focused High Blood Pressure Intervention | Intervention Type: BEHAVIORAL; Name: Health Literacy-Focused High Blood Pressure Intervention; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Cross-Over Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)
Brief Summary: The primary objective is to determine if the opioid properties of ketamine are responsible for its antidepressant effects. Since naltrexone can block opiate actions, the investigators will determine if naltrexone can effectively block ketamine's effects.


Options:
A: Arm Label: A: Ketamine + Naltrexone or placebo; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: B: Ketamine + Naltrexone or placebo; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): A: Ketamine + Naltrexone or placebo, B: Ketamine + Naltrexone or placebo
B: Arm Label: sarcosine; Type: EXPERIMENTAL; Interventions: Drug: sarcosine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: sarcosine; Assigned to Arm(s): sarcosine
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1
D: Arm Label: Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Cross-Over Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)
Brief Summary: The primary objective is to determine if the opioid properties of ketamine are responsible for its antidepressant effects. Since naltrexone can block opiate actions, the investigators will determine if naltrexone can effectively block ketamine's effects.


Options:
A: Arm Label: sarcosine; Type: EXPERIMENTAL; Interventions: Drug: sarcosine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: sarcosine; Assigned to Arm(s): sarcosine
B: Arm Label: A: Ketamine + Naltrexone or placebo; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: B: Ketamine + Naltrexone or placebo; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): A: Ketamine + Naltrexone or placebo, B: Ketamine + Naltrexone or placebo
C: Arm Label: memantine; Type: EXPERIMENTAL; Interventions: Drug: memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RO4917523 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4917523 0.5 mg | Arm Label: RO4917523 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4917523 1.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO4917523 0.5 mg; Assigned to Arm(s): RO4917523 0.5 mg | Intervention Type: DRUG; Name: RO4917523 1.5 mg; Assigned to Arm(s): RO4917523 1.5 mg

Answer: B